BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32348468)

  • 1. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
    Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
    Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
    Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
    Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
    Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
    Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
    Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
    Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis.
    Zivancevic-Simonovic S; Mihaljevic O; Majstorovic I; Popovic S; Markovic S; Milosevic-Djordjevic O; Jovanovic Z; Mijatovic-Teodorovic L; Mihajlovic D; Colic M
    Cancer Immunol Immunother; 2015 Aug; 64(8):1011-9. PubMed ID: 25971541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape
    Hu JQ; Lei BW; Wen D; Ma B; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Li DS; Ji QH; Liao T
    J Cancer; 2020; 11(14):4250-4260. PubMed ID: 32368308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
    Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
    J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.
    Pakkanen E; Kalfert D; Ahtiainen M; Ludvíková M; Kuopio T; Kholová I
    APMIS; 2022 May; 130(5):276-283. PubMed ID: 35238073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis.
    Mohamed SY; Ibrahim TR; Elbasateeny SS; Abdelaziz LA; Farouk S; Yassin MA; Embaby A
    Sci Rep; 2020 Jun; 10(1):10651. PubMed ID: 32606302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic relationship between Hashimoto`s thyroiditis and papillary thyroid carcinoma with coexisting Hashimoto`s thyroiditis.
    Subhi O; Schulten HJ; Bagatian N; Al-Dayini R; Karim S; Bakhashab S; Alotibi R; Al-Ahmadi A; Ata M; Elaimi A; Al-Muhayawi S; Mansouri M; Al-Ghamdi K; Hamour OA; Jamal A; Al-Maghrabi J; Al-Qahtani MH
    PLoS One; 2020; 15(6):e0234566. PubMed ID: 32603365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto's thyroiditis.
    Zhang Y; Tian Y
    BMC Endocr Disord; 2022 Oct; 22(1):252. PubMed ID: 36266640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
    Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
    Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S
    Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis.
    Stanciu AE; Serdarevic N; Hurduc AE; Stanciu MM
    Scand J Clin Lab Invest; 2015 Nov; 75(7):539-48. PubMed ID: 26305420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
    Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
    Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics analysis identified shared differentially expressed genes as potential biomarkers for Hashimoto's thyroiditis-related papillary thyroid cancer.
    Liu C; Pan Y; Li Q; Zhang Y
    Int J Med Sci; 2021; 18(15):3478-3487. PubMed ID: 34522174
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
    Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
    Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes.
    Xu S; Huang H; Qian J; Liu Y; Huang Y; Wang X; Liu S; Xu Z; Liu J
    JAMA Netw Open; 2021 Jul; 4(7):e2118526. PubMed ID: 34313737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.